Reference : Le cas clinique du mois. Hepatite cholestatique apres administration de piperacilline.
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/17296
Le cas clinique du mois. Hepatite cholestatique apres administration de piperacilline.
French
[en] Clinical case of the month. Cholestatic hepatitis after administration of piperacillin
Dietze, M. A. [> > >]
Martin, Pierre mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Schaaf-Lafontaine, Nicole mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie biologique et immuno hématologie >]
2002
Revue Médicale de Liège
57
9
571-4
Yes (verified by ORBi)
International
0370-629X
Belgium
[en] Cholestasis/chemically induced ; Female ; Hepatitis, Toxic/pathology ; Humans ; Lymphocyte Activation ; Middle Aged ; Penicillins/adverse effects/therapeutic use ; Piperacillin/adverse effects/therapeutic use ; Respiratory Tract Infections/drug therapy
[en] We describe a patient suffering from infection of the upper respiratory tract, who was treated with a dose of 4 x 4 g of piperacillin over 10 days. Two days after the end of the treatment, she developed jaundice and had elevated alkaline phosphatase, gammaglutamyltransferase and transaminases. After exclusion of viral hepatitis, a vascular problem, and gall stone disease, the possibility of piperacillin-induced hepatitis was discussed. Lymphocyte transformation test for piperacillin was positive, suggesting an immunological mechanism for the observed hepatopathy. The patient was discharged a few days after in good clinical condition and with reduced liver values. Cholestasis gradually decreased but was detectable for several weeks. The patient had a full clinical and biochemical recovery after 2 months. We conclude that short-term therapy with piperacillin can lead to the same type of hepatopathy as described for amoxycillin/clavulanic acid or antistaphylococcal penicillins. Positive lymphocyte transformation is compatible with an immunological mechanism.
Researchers
http://hdl.handle.net/2268/17296

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
schaaf le cas clinique 2002.pdfNo commentaryPublisher postprint436.11 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.